

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### MTA Autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (including a review of TA89)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

The interventions ChondroCelect and MACI require the use of animal-derived products (namely from bovine or porcine origin). This may be an issue for people with particular religious and cultural beliefs who have objections to the use of certain animal products. This cannot be addressed in this technology appraisal.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No further equality issues have been raised.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

The Committee did not identify any equality issues.
---

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No.

**Approved by Associate Director (name):** Elisabeth George

**Date:** 06/03/2015

## Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations are optimised to the population who are expected to have the greatest clinical benefit from ACI. One of the optimisations is that there is minimal osteoarthritic damage to the knee, and therefore excludes people with advanced or severe osteoarthritis which can be disabling. However, one of the contraindications in the marketing authorisation for the technology is advanced osteoarthritis.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No because the technology is not licensed for use in people with advanced osteoarthritis.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The committee did not stipulate any specific threshold for the level of osteoarthritis, but instead stated in the guidance that it was appropriate for clinicians experienced in investigating knee cartilage damage to assess suitability for ACI using a validated measure for osteoarthritis of the knee.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes in section 3.26

**Approved by Centre or Programme Director (name):** Elisabeth George

**Date:** 18/07/2017

